Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) Director Jon Faiz Kayyem purchased 69,686 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the transaction, the director now directly owns 51,093 shares of the company’s stock, valued at $727,053.39. This trade represents a -374.80 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Inhibrx Stock Performance
NASDAQ INBX traded up $0.10 during midday trading on Friday, hitting $14.08. The company had a trading volume of 54,284 shares, compared to its average volume of 138,526. The firm has a fifty day simple moving average of $15.66 and a two-hundred day simple moving average of $17.34. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $18.95.
Hedge Funds Weigh In On Inhibrx
Several large investors have recently added to or reduced their stakes in INBX. Price T Rowe Associates Inc. MD raised its stake in shares of Inhibrx by 8.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock valued at $518,000 after purchasing an additional 1,112 shares in the last quarter. Black Maple Capital Management LP acquired a new stake in shares of Inhibrx during the 1st quarter worth about $555,000. Finally, Alpine Global Management LLC bought a new position in Inhibrx in the 1st quarter valued at $1,224,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
- Five stocks we like better than Inhibrx
- What is the Dogs of the Dow Strategy? Overview and Examples
- Tesla Investors Continue to Profit From the Trump Trade
- What is Insider Trading? What You Can Learn from Insider Trading
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- Options Trading – Understanding Strike Price
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
